[{"data":1,"prerenderedAt":156},["ShallowReactive",2],{"drug-linagliptin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":20,"formulations":24,"regimens":39,"contraindications":55,"warnings":65,"renal":73,"monitoring":74,"interactions":75,"review":76,"examples":79,"atc":85,"iran":87,"links":99,"populations":116,"usApproval":151},"linagliptin",1,{"fa":7,"en":8},"لیناگلیپتین","Linagliptin","alimentary-metabolism",{"fa":11,"en":12},"مهارکننده DPP-4","DPP-4 inhibitor",[14,17],{"name":15,"market":16},"Tradjenta","US",{"name":18,"market":19},"Trajenta","GB",[21,22,23,7],"trajenta","tradjenta","ترجنتا",[25],{"id":26,"form":27,"route":28,"label":29,"concentration":30,"markets":34,"refs":35},"tab-5","tablet","oral","5 mg tablet",{"amount":31,"unit":32,"perUnit":27,"scored":33},5,"mg",false,[16],[36],{"source":37,"section":38},"fda-linagliptin","3",[40],{"id":41,"disease":42,"label":43,"population":46,"type":50,"unit":32,"dose":51,"refs":52},"t2","type-2-diabetes",{"fa":44,"en":45},"دیابت نوع ۲ — ۵ mg یک بار در روز","Type 2 diabetes — 5 mg once daily",{"minAge":47},{"value":48,"unit":49},18,"year","fixed",{"perDose":31,"dosesPerDay":5},[53],{"source":37,"section":54},"2.1",[56],{"id":57,"severity":58,"text":59,"refs":62},"hyper","block",{"fa":60,"en":61},"حساسیت به لیناگلیپتین (آنافیلاکسی، آنژیوادم…).","Hypersensitivity to linagliptin (anaphylaxis, angioedema…).",[63],{"source":37,"section":64},"4",[66],{"text":67,"refs":70},{"fa":68,"en":69},"پانکراتیت؛ پمفیگوئید تاولی؛ درد شدید مفاصل.","Pancreatitis; bullous pemphigoid; severe joint pain.",[71],{"source":37,"section":72},"5",[],[],[],{"status":77,"reviewer":78,"date":78},"unverified",null,[80],{"regimen":41,"formulation":26,"input":81,"expect":84},{"ageYears":82,"weightKg":83},55,85,{"perDose":31,"tabletsPerDoseRounded":5},[86],"A10BH05",{"status":88,"forms":89,"refs":94},"registered",[90],{"code":91,"en":92,"fa":93},"51883","LINAGLIPTIN 5 mg TABLET","قرص لیناگلیپتین ۵ میلی‌گرم",[95],{"source":96,"section":97,"url":98},"darooyab-generic","G-3682\u002FLinagliptin","https:\u002F\u002Fwww.darooyab.ir\u002FG-3682\u002FLinagliptin",[100,104,108,111,114],{"kind":101,"url":102,"label":103},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=201280","NDA201280",{"kind":105,"url":106,"label":107},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f","FDA Tradjenta",{"kind":109,"url":110,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa611036.html",{"kind":112,"url":113,"label":86},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BH05",{"kind":115,"url":98,"label":8},"darooyab",{"pregnancy":117,"lactation":126,"pediatric":134,"geriatric":142},{"level":118,"text":119,"quote":122,"refs":123},"caution",{"fa":120,"en":121},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited data with TRADJENTA use in pregnant women are not sufficient to inform of drug-associated risk for major birth defects and miscarriage.",[124],{"source":37,"section":125},"8.1",{"level":118,"text":127,"quote":130,"refs":131},{"fa":128,"en":129},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of linagliptin in human milk, the effects on the breastfed infant, or the effects on milk production.",[132],{"source":37,"section":133},"8.2",{"level":118,"text":135,"quote":138,"refs":139},{"fa":136,"en":137},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of TRADJENTA have not been established in pediatric patients.",[140],{"source":37,"section":141},"8.4",{"level":143,"text":144,"quote":147,"refs":148},"ok",{"fa":145,"en":146},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","In these linagliptin studies, no overall differences in safety or effectiveness of linagliptin were observed between geriatric patients and younger adult patients.",[149],{"source":37,"section":150},"8.5",{"kind":152,"refs":153,"id":103},"NDA",[154],{"source":37,"section":155},"SPL approval \u002F marketing category",1792092037959]